GLP-1 agonists like Wegovy® (semaglutide) and Zepbound® (tirzepatide) are revolutionizing weight loss, with users shedding 15-22% of body weight on average. Originally designed for type 2 diabetes, these medications now dominate obesity treatment—searches for “GLP-1 agonist weight loss” surged 400% in 2023. Here’s what you need to know. How GLP-1 Agonists Work: Science Made Simple GLP-1 agonists mimic […]
English 
Nederlands